October 1, 2021
AstraZeneca’s SGLT2 inhibitor Forxiga (dapagliflozin) could treat up to 3 million patients with chronic kidney disease (CKD) in Japan following its label expansion in August, a nephrologist said on September 30 at a seminar sponsored by the company and partner...read more